(IN BRIEF) ViiV Healthcare has received approval from China's National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with…
The ATLAS-2M study will evaluate injections every two months in virally suppressed patients LONDON, 29-Nov-2017 — /EuropaWire/ — Today (27 November…